Image 1
Chemical structure of Docetaxel, the active pharmaceutical ingredient depicted in the image.*
Docetaxel Injection, Solution, Concentrate
Product Images NDC 45963-734
15 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 45963-734). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 10
A survival probability curve comparing two treatment groups labeled TPF and PF over time in months. The graph shows survival probability on the y-axis and survival time in months on the x-axis, illustrating a higher survival probability trend for the TPF group compared to the PF group up to 72 months.*
Image 11
A line graph showing survival probability (%) over time (months) comparing two patient groups: TPF (n=255) and PF (n=246). The graph includes survival probability curves and a table indicating the number of patients at risk at various time points for both groups.*
Image 12
Text panel providing instructions on oral corticosteroid dosing schedules for patients receiving Docetaxel Injection for various cancers, including breast, non-small cell lung, stomach, head and neck cancers, and prostate cancer. It outlines specific days and times for medication administration related to Docetaxel treatment days.*
Image 13
Packaging label for Docetaxel Injection USP 20 mg/mL solution concentrate for intravenous infusion by Actavis Pharma, Inc. The label indicates a single-dose vial containing 1 mL, marked with a red caution for cytotoxic agent. It includes manufacturing information from Romania and dosage preparation instructions. The NDC is 45963-734-54.*
Image 14
Packaging label for Docetaxel Injection USP 80 mg/4 mL (20 mg/mL) concentrate for intravenous infusion by Actavis Pharma, Inc. The carton highlights a 4 mL single-dose vial, cautions on cytotoxicity, and includes usage notes and storage conditions. The label shows manufacturing and distribution details, barcode, and NDC 45963-765-52.*
Image 15
Box label for Docetaxel Injection USP, 160 mg/8 mL (20 mg/mL), an intravenous injection concentrate. The label includes the Actavis logo and states the product is a single-dose vial, preservative-free, and for intravenous infusion only. It contains caution notes about its cytotoxic nature and specifies storage instructions and ingredients. The label also lists the distributor as Actavis Pharma, Inc., Parsippany, NJ, USA.*
Image 2
A line graph depicting disease-free survival probability (%) over time in months for two treatment groups labeled TAC and FAC. The graph shows a decline in survival probability from 0 to 66 months, with TAC maintaining a higher disease-free survival probability than FAC throughout the period.*
Image 3
A survival probability curve comparing two treatments labeled TAC and FAC. The x-axis represents survival time in months, ranging from 0 to 66, and the y-axis shows survival probability as a percentage from 0 to 100%. The graph depicts survival trends over time for the two treatment groups.*
Image 4
A Kaplan-Meier survival curve graph showing cumulative probability versus survival time in months. Two curves compare the groups labeled T75 (solid line) and BSC (dashed line), with the T75 group demonstrating higher survival probability over time. The graph includes a log-rank p value of 0.010 indicating statistical difference in overall survival between groups.*
Image 5
A Kaplan-Meier survival curve chart showing cumulative probability of overall survival over time in months. The chart compares two groups, labeled T75 and V/I, with survival probabilities plotted on the vertical axis and survival time in months on the horizontal axis. The chart indicates a log-rank p value of 0.13 for overall survival comparison between the groups.*
Image 6
A survival probability curve chart depicting survival time in months on the x-axis versus survival probability on the y-axis. Two lines are shown: one solid labeled T75 q3w and one dashed labeled M q3w, illustrating comparative survival probabilities over a 30-month period.*
Image 7
A Kaplan-Meier survival curve graph comparing two groups labeled TCF and CF. The vertical axis represents Probability (%) and the horizontal axis represents Time (months) over a 24-month period. The solid line corresponds to TCF and the dashed line corresponds to CF, showing survival probabilities declining over time for both groups.*
Image 8
A survival curve chart showing survival probability (%) on the vertical axis and survival time (months) on the horizontal axis. Two groups, labeled TCF and CF, are compared with distinct curves illustrating their survival probabilities over a 36-month period.*
Image 9
A Kaplan-Meier survival curve chart depicting Progression Free Survival (PFS) Probability (%) over time in months. The graph shows two plotted lines representing TPF and PF treatment groups, tracking their respective PFS probabilities up to 42 months.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
